Preclinical services in oncology

Selecting in vitro the most active candidate

Before advancing to in vivo studies, the selection of the most effective lead candidate is essential for minimizing risk and maximizing therapeutic potential. We offer in vitro assays designed to screen and evaluate the cytotoxicity and efficacy of your compounds. Our platforms enable rapid screening of multiple candidates, including the use of tumor cell lines and 3D tumor models to identify the most promising drug candidates for further development (see In Vitro section for more details).

Deciphering the mechanisms of action of your therapeutic antibodies and compounds

Refining the effectiveness and safety profiles of your therapeutic antibodies requires an understanding of their underlying mechanisms of action. In order to assess the mechanisms of action of monoclonal antibodies, ADCs, bispecifics, and other antibody-based therapies, we offer specialized research services to investigate how antibodies affect immune responses, interact with tumor antigens, and enhance immune cell functioning. These insights are critical for optimizing immunotherapies and improving their clinical translation (see Development of Immunotherapies section for more details).

In addition to antibodies, we also provide service to evaluate the mechanisms of action of small molecules and other chemical compounds. Through end-point studies and continuous monitoring, we can investigate how your compound interacts with tumor cells, alters cellular signaling pathways, and affects tumor progression. Our team uses a range of biomarker assays to identify and validate the key pathways involved, helping you understand how your compound can be optimized for enhanced anticancer activity. For further information, please refer to our End Point Studies and Continuous Monitoring section.

Choosing the best indication and model for the development of your compound

Selecting the appropriate preclinical tumor models is a critical step in understanding the potential of your compound across different cancer types. Antineo offers a diverse range of tumor models, including CDX (patient-derived xenografts) and syngeneic models, to help identify the most relevant cancer indications for your compound. By carefully selecting the right model that mirrors the tumor’s biology and immune environment, we ensure that the preclinical data generated will be predictive of clinical outcomes (see Tumor Models section for more details).

Performing proof of concept studies of the antitumor efficacy of your therapeutics

Once you’ve identified your lead candidate, Proof of Concept (PoC) studies are essential to demonstrate the antitumor efficacy of your compound in preclinical models. We are here to design and conduct in vivo PoC studies to evaluate the therapeutic potential of your compounds in immunocompromised, immunocompetent, or humanized mouse models. We assess critical factors such as tumor growth inhibition, immune population modulations, and long-term survival to establish the efficacy and therapeutic window of your compound before moving to clinical trials (see In Vivo section for more details).

Developing tailored experiments according to your needs

We recognize that every project is unique, this is the reason why we offer tailored experimental designs to meet your specific research objectives. Whether you are looking to explore a novel mechanism of action, optimize dosing strategies, or investigate combination therapies, we are committed to providing customized services that align with your goals. Our flexibility, coupled with our extensive experience in oncology research, allows us to adapt our services to any specific therapeutic area or scientific challenge.

Our commitment to scientific collaboration

At Antineo, we are first and foremost scientists. We are passionate about innovation and are always open to working with our clients to develop new services or experimental approaches that address emerging challenges in oncology research. We want to offer the highest collaboration relationship to our clients, by keeping the communication at the center and providing you with the tools and expertise necessary for success.

If you have an assay or experiment that is not listed in our services, we welcome the opportunity to discuss how we can collaborate to meet your needs. Feel free to contact us to explore how we can assist in developing custom solutions for your preclinical oncology research.